Application for Emergency Use Authorization of investigational single-dose Janssen Covid-19 vaccine submitted to the US FDA

The submission is based on recently released data from the Phase III ENSEMBLE trial, in which all primary and key secondary endpoints were met. The company will submit a Conditional Marketing Authorisation Application with the European Medicines Agency in the coming weeks.

Source:

Biospace Inc.